Immunotherapy and Molecular Tumor Therapy Networks of Excellence
The Cancer Center is divided into eleven specialized cancer centers. In order to take account of the further development of oncology, these are supplemented by two networks of excellence that serve as cross-sectional services. By establishing these two networks of excellence, our Cancer Center has entered a new era of oncology to ensure that our patients receive individual, interdisciplinary care based on the latest findings.
The networks interact closely with the individual specialized cancer centers and develop guidelines for diagnostics, therapy and side effects management. They serve as coordination centers for clinical and translational research projects and both have established their own cancer boards.
Immunotherapy
The Immunotherapy Board meets once a month. Here, immunotherapy patients are discussed individually by the participating specialists from different disciplines, and therapies are determined. In doing so, great care is taken to control or avoid the side effects of the therapy. In addition, new immune strategies should be intelligently combined with existing therapeutic approaches in order to achieve maximum effect.
The continuous updates of shared knowledge and clinical expertise benefit patients, while the therapeutic strategies are constantly updated in line with the international standards. We also aim to participate in innovative studies in close cooperation with the referring doctors in the region.
Office hours
Monday: Prof. Alfred Zippelius
Friday: Dr. Heinz Läubli
Registration
University Hospital Basel
Oncology Clinic
Petersgraben 4
4031 Basel
Tel. +41 61 265 50 74/59
onkologie@usb.ch
Leitung
Team
Prof. Jörg Halter
Leitender Arzt
Hämatologie
Dr. Kathleen Jahn
Kaderärztin, ärztliche Leitung interventionelle Pneumologie
Pneumologie
Prof. Dr. Gabriela Kuster Pfister
Kaderärztin
Kardiologie
Dr. Lara Valeska Maul-Duwendag
Kaderärztin
Dermatologie
Prof. Jan Hendrik Niess
Leitender Arzt Gastroenterologie/Hepatologie
Clarunis
Molecular therapy
Since September 2015, the Molecular Tumor Board is the first of its kind in Switzerland to be held every two weeks. Therapy decisions are made here based on the genomic sequencing of tumors. The sequencing data is interpreted by the molecular pathologists, biologists and medical geneticists in order to make therapeutic decisions together with the medical oncologists and hematologists.
The well-established Tumor Board discusses patient findings from a variety of disciplines. For example, benign rheumatology diseases are also discussed in order to take advantage of the Board’s interdisciplinary nature.
Office hours
Associate Prof. Dr. med. Dr. phil. Sacha Rothschild
Thursday: 2:30 p.m.–4:30 p.m.
Registration
University Hospital Basel
Oncology Clinic
Petersgraben 4
4031 Basel
Tel. +41 61 265 50 74/59
onkologie@usb.ch
Leitung
PD Dr. Benjamin Kasenda
Leitender Arzt
Onkologie
Gastrointestinale Tumore,
Mitglieder
Dr. Pirmin Häuptle
Prof. Dr. med. Dr. phil. nat. Karl Heinimann
Stv. Ärztlicher Leiter
Medizinische Genetik
PD Dr. Matthias Matter
Leitender Arzt und Fachbereichsleiter Molekularpathologie
Pathologie
Tel. +41 61 328 64 71
PD Dr. Kirsten Mertz
Tel. +41 61 925 26 35